EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective

Zobair M Younossi, Homie Razavi, Michael Sherman, Alina M Allen, Quentin M Anstee iD, Kenneth Cusi iD, Scott L Friedman, Eric Lawitz, Jeffrey V Lazarus iD, Detlef Schuppan iD, Manuel Romero-Gómez iD, Jörn M Schattenberg und 6 weitere

Alimentary Pharmacology & Therapeutics · 2025-05 · 61 (9) · 1467-1478

DOI: 10.1111/apt.70020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 18.02.2025. Verfasst von Zobair M Younossi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolic Diseases. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: ProSciento Inc., USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well‐being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non‐invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD‐related problem.

Aim

The aim of this article was to summarise the global burden of MASLD from the payer's perspective.

Methods

We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient‐reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively.

Conclusion

The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs. Trial Registration: NCT06309992

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMetabolic SyndromeMetabolic DiseasesHumansPrevalenceGlobal HealthCost of IllnessGlobal Burden of DiseaseHealth Care Costs

Stichwörter der Autor:innen

metabolic continuummetabolic diseasemetabolic dysfunction‐associated steatotic liver diseasetype 2 diabetes mellitus

Autor:innen und Institutionen

  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
  • The Global NASH Council, Washington, DC, USA.
  • Center for Disease Analysis Foundation, Lafayette, Colorado, USA.
  • RA Capital Management, L.P., Boston, Massachusetts, USA.
  • Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic Minnesota, Rochester, Minnesota, USA.

ORCID-Profile: Quentin M Anstee, Kenneth Cusi, Jeffrey V Lazarus, Detlef Schuppan, Manuel Romero-Gómez, Vincent Wai-Sun Wong, Arun J Sanyal, Rohit Loomba

Förderung

  • ProSciento Inc., USA

Zitieren

APA

Younossi, Z. M., Razavi, H., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., Romero-Gómez, M., Schattenberg, J. M., Vos, M. B., Wong, V. W., Ratziu, V., Hompesch, M., Sanyal, A. J., & Loomba, R. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics, 61(9), 1467-1478. https://doi.org/10.1111/apt.70020

Vancouver

Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, et al. Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics. 2025;61(9):1467-1478. doi:10.1111/apt.70020

BibTeX
@article{Younossi2025,
  author = {Younossi, Zobair M and Razavi, Homie and Sherman, Michael and Allen, Alina M and Anstee, Quentin M and Cusi, Kenneth and Friedman, Scott L and Lawitz, Eric and Lazarus, Jeffrey V and Schuppan, Detlef and Romero-Gómez, Manuel and Schattenberg, Jörn M and Vos, Miriam B and Wong, Vincent Wai-Sun and Ratziu, Vlad and Hompesch, Marcus and Sanyal, Arun J and Loomba, Rohit},
  title = {Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {9},
  pages = {1467--1478},
  doi = {10.1111/apt.70020}
}
Kostenlos starten →